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ABSTRACT 
Methionine (Met) is an amino acid essential for 
many important cellular and biosynthetic functions, 
including the initiation of protein synthesis and S-
adenosylmethionine-mediated methylation of 
proteins, RNA, and DNA. The de novo biosynthetic 
pathway of Met is well conserved across 
prokaryotes but absent from vertebrates, making it 
a plausible antimicrobial target. Using a systematic 
approach, we examined the essentiality of de novo 
methionine biosynthesis in Salmonella enterica 
serovar Typhimurium, a bacterial pathogen causing 
significant gastrointestinal and systemic diseases in 
humans and agricultural animals. Our data 
demonstrates that Met biosynthesis is essential for 
S. Typhimurium to grow in synthetic media and 
within cultured epithelial cells where Met is 
depleted in the environment. During systemic 
infection of mice, the virulence of S. Typhimurium 
was not affected when either de novo Met 
biosynthesis or high-affinity Met transport was 
disrupted alone, but when disrupted in combination 
led to severe in vivo growth attenuation, 
demonstrating a functional redundancy between de 
novo biosynthesis and acquisition as a mechanism 
of sourcing Met to support growth and virulence for 
S. Typhimurium during infection. In addition, our 
LC-MS analysis revealed global changes in the 
metabolome of S. Typhimurium mutants lacking 
Met biosynthesis, and also uncovered unexpected 
interactions between Met and peptidoglycan 
biosynthesis. Together, this study highlights the 
complexity of the interactions between a single 
amino acid, Met, and other bacterial processes 
leading to virulence in the host, and indicates that 
disrupting the de novo biosynthetic pathway alone 
http://www.jbc.org/cgi/doi/10.1074/jbc.RA118.002592The latest version is at 
JBC Papers in Press. Published on May 2, 2018 as Manuscript RA118.002592
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is likely to be ineffective as an antimicrobial 
therapy against S. Typhimurium. 
 
INTRODUCTION 
Methionine (Met) is a sulphur-containing 
proteinogenic amino acid that is required for the 
initiation of protein synthesis (1). S-adenosyl 
methionine (SAM), a downstream derivative of 
Met, acts as a major methyl donor in the cell and 
methylates a variety of macromolecules such as 
DNA, RNA, protein and lipids (2). A de novo 
pathway for Met biosynthesis is present in the vast 
majority of prokaryotes, albeit with variations in 
the enzymes that drive the biosynthetic cascade 
(3,4). In contrast, the full de novo Met biosynthesis 
is absent from vertebrates, which must obtain this 
amino acid through external sources such as diet 
and gut flora (5,6). In recent years, it has been 
increasingly recognised that central metabolism 
represents a promising yet underexploited area for 
the development of antimicrobial drugs (7). The 
apparent essentiality in microbes and absence in 
mammals makes the Met biosynthetic pathway an 
especially attractive target for antimicrobial 
therapy. 
Salmonella enterica is a Gram-negative, 
facultative intracellular bacterium which causes 
gastrointestinal and systemic diseases in animals 
and humans. There are approximately 2500 
serovars in this species which include the human-
adapted enteric fever pathogens S. enterica var. 
Typhi and Paratyphi, and invasive non-typhoidal 
Salmonella (iNTS), alongside serovars that cause 
debilitating gastroenteritis, including S. enterica 
var. Typhimurium (8,9). For all Salmonella 
serovars, the capacity to grow in the host is central 
to bacterial virulence (10). In mammalian hosts, S. 
enterica grows in the blood and reticuloendothelial 
system largely within a defined, membrane-bound 
endocytic compartment called the Salmonella-
containing vacuole (SCV) (11,12). The extent to 
which S. enterica salvages essential nutrients from 
the lumen of the SCV and the nutrient composition 
of this vacuole remains poorly defined, and the 
micronutrient environment of the SCV has not been 
fully resolved. Ex vivo, S. enterica is capable of 
growth in minimal media containing glucose as a 
carbon source, and key ions, and the metabolic 
potential of this species has been recognised and 
mapped (13). It is less clear though how this 
considerable capability is exploited for maximal 
growth in vivo. The essentiality of the pathways can 
only be determined by systematic analysis in vitro 
and in animal models, and fine mapping is required 
to determine whether essential pathways contain 
novel targets for antibiotic development.  
The de novo biosynthetic pathway for Met 
has been previously reported in S. enterica (Fig. 1). 
This pathway is regulated by the transcription 
factors MetJ and MetR (14). With its co-repressor 
SAM, MetJ represses the transcription of all met 
genes except metH (15). In contrast, MetR is an 
autoregulated transcriptional activator that controls 
the expression of metA, metF, metE, metH, (16). In 
addition to de novo biosynthesis, S. enterica is able 
to acquire Met from extracellular sources through a 
high-affinity transporter that is encoded by the 
metD locus, encoding an ATP Binding Cassette 
(ABC) transporter composed of three subunits: the 
ATPase (MetN), a transmembrane permease (MetI) 
and a periplasmic Met binding protein (MetQ). 
Biochemical analysis has shown that MetNIQ 
transports both the D- and L-enantiomers of Met 
(17,18). In the absence of the high-affinity MetNIQ 
transporter system, genetic analysis has suggested 
that S. enterica is able to transport Met at much 
lower affinity, through a putative and cryptic low-
affinity Met transporter system termed ‘MetP’ (19-
21). In contrast to MetNIQ, MetP transports L-Met 
but not D-Met, and the coding gene(s) for MetP 
remains unidentified to-date. !
S. enterica may encounter markedly 
different nutrient levels during local (e.g. the gut) 
and systemic (e.g. the spleen and liver) infections 
which, in turn, may vary the bacterium’s 
dependence on de novo biosynthesis and nutrient 
import pathways for growth in different tissue 
niches. The enzymes required for Met biosynthesis 
and the Met transporter have been implicated in the 
virulence of S. enterica and other bacteria (22-28). 
However, these pathways have not been 
systematically investigated for their role in the 
virulence of S. enterica. The aim of this study was 
to investigate the essentiality of de novo 
biosynthesis and transport of Met in the growth and 
virulence of S. Typhimurium in vitro and in vivo. 
 
Results 
In vitro validation of the Met biosynthetic pathway 
in S. Typhimurium and growth of defined Met 
auxotrophs in mice 
Previous transcriptional analyses of S. 
Typhimurium grown in media and in tissue culture 
cells have demonstrated that the genes involved in 
the de novo Met synthesis pathway (metA, metB, 
metC, metE, metF and metH) are expressed under a 
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variety of growth conditions (Supplementary Fig. 
S1, deduced from (29)). While the expression level 
of the de novo pathway is relatively low in rich 
media, much stronger expression was observed 
under growth conditions where the Salmonella 
Pathogenicity Island-2 (SPI-2) genes were 
expressed, or when the bacteria were inside 
macrophages (30). 
Defined mutants in the Met biosynthetic 
pathway: ∆metA, ∆metB, ∆metC, ∆metE, ∆metF, 
∆metH and ∆metE∆metH, were generated in S. 
Typhimurium SL1344, sequenced and tested for 
their ability to grow in M9 minimal media, with or 
without added L-Met, and in nutrient-rich media 
(LB). All mutants grew in LB media at a rate 
comparable to wild-type SL1344 (data not shown). 
In M9 minimal media supplemented with Met, Met 
mutants grew as efficiently as SL1344 over a 24-
hour period (Fig. 2A), suggesting that the absence 
of the de novo biosynthetic pathway was 
compensated by the transport of exogenously 
available Met. As expected, the ∆metA, ∆metB, 
∆metC, ∆metE and ∆metF mutants exhibited Met 
auxotrophy in M9 media whereas ∆metH showed 
substantial growth over the 24-hour period (Fig. 
2A), confirming that MetH is not essential for de 
novo biosynthesis of Met under aerobic conditions 
(31,32). The growth of the ∆metH mutant in M9 
media was apparently supported by a functional 
Met synthase, i.e. MetE, as ∆metE∆metH failed to 
grow in M9 media in the absence of exogenous Met 
(Fig. 2A). It has been suggested that the 
functionality of MetH in E. coli is vitamin B12-
dependent (33). To test whether there is an 
equivalent dependence in S. Typhimurium, ∆metE, 
∆metH and ∆metE∆metH mutants were grown in 
M9 media with or without vitamin B12. All three 
mutants grew in the presence of vitamin B12 (Fig. 
2B). The ∆metE mutant, which was dependent on 
MetH to synthesise Met, grew only when vitamin 
B12 was added (Fig. 2B), confirming that MetH 
activity in S. Typhimurium is vitamin B12-
dependent. As S. Typhimurium synthesises vitamin 
B12 only under anaerobic conditions (31), growth 
of the ∆metE mutant in M9 media should have been 
restored when oxygen was depleted. Indeed, 
∆metE, ∆metH and ∆metE∆metH both grew in M9 
media under anaerobic conditions and phenocopied 
their growth in M9 media with vitamin B12 under 
aerobic conditions (Fig. 2C). These observations 
are consistent with an understanding that S. 
Typhimurium synthesises vitamin B12 under 
anaerobic conditions, and support a level of 
functional redundancy between MetE and MetH 
during de novo biosynthesis of Met in S. 
Typhimurium. 
To assess the requirement for de novo Met 
synthesis for intracellular bacterial growth, HeLa 
cells were infected with S. Typhimurium wild-type 
and mutants, and the intracellular bacterial load was 
assessed after 2, 5 and 10 hours. When HeLa cells 
were cultivated in DMEM growth media lacking 
Met, the intracellular growth of ∆metA, ∆metB, 
∆metC and ∆metF was significantly attenuated 
compared with the wild-type control (Fig. 2D). The 
∆metE mutant only showed obvious growth after 5 
hours. In contrast, the ∆metH mutant showed 
intracellular growth comparable to SL1344, 
suggesting that a functional MetE is sufficient for 
supporting intracellular replication in the SCV (Fig. 
2D). Importantly, when HeLa cells were cultivated 
in DMEM containing physiological levels of L-
Met, none of the mutants showed any significant 
defect in intracellular growth (Supplementary Fig. 
S2), demonstrating that exogenous Met can rescue 
Met auxotrophy, presumably reflecting direct or 
indirect transport of Met from the culture media to 
the lumen of the bacterial-occupied SCV.  
Previous reports have proposed that Met 
biosynthesis might be required for virulence of S. 
Typhimurium in mice or chickens (24,34). To test 
this requirement in mice, the virulence of individual 
de novo biosynthetic mutants was studied in 
C57BL/6 mice, in which wild-type SL1344 is fully 
virulent and invariably results in a systemic, lethal 
infection (35,36). Groups of mice were infected 
with 200 cfu of the different Met auxotrophic 
mutants intravenously and, at day 5 post-infection, 
mice were culled and the bacterial load in the liver 
(Fig. 2E) and spleen (Fig. 2F) was determined by 
viable count. The number of bacteria recovered 
from mice infected with the mutants was 
comparable to those from mice infected with 
SL1344. Hence, none of the mutants showed 
virulence defects in mice following intravenous 
infection. Another group of mice were infected 
orally with ∆metB, ∆metE, ∆metH or 
∆metE∆metH. The bacterial load in the spleen and 
liver of mice infected with the mutant strains was 
comparable to those from mice infected with the 
wild-type S. Typhimurium (Supplementary Fig. 
S3). These data showed that de novo Met 
biosynthesis is not essential for the growth of S. 
Typhimurium in C57BL/6 mice, regardless of the 
route of infection. 
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Met auxotrophs deficient in the high-affinity 
transporter (MetNIQ) are attenuated in mice 
Our observation that S. Typhimurium 
mutants were able to grow intracellularly and in 
vivo without a functional de novo Met biosynthetic 
pathway suggested that Met acquisition via the 
transporters may play an important role in bacterial 
virulence. To test this hypothesis, a high-affinity 
transporter mutant of S. Typhimurium, ∆metNIQ, 
was constructed. As expected, the ∆metNIQ mutant 
grew in M9 minimal media in the absence of Met 
supplementation (Fig. 3A), suggesting that the 
high-affinity Met transporter is not essential for 
growth in M9 media provided that de novo 
synthesis is intact.  
To determine whether dual mutations in de 
novo biosynthesis and the high-affinity transporter 
of Met affected the growth of S. Typhimurium in 
vitro and in vivo, ∆metNIQ∆metEH and 
∆metNIQ∆metB mutants were generated. As 
expected, the ∆metNIQ∆metEH and 
∆metNIQ∆metB mutants were unable to grow in 
M9 minimal media without added Met (Fig. 3B); 
this Met auxotrophy confirms that a combined 
deficiency in both biosynthesis and high-affinity 
transport is inhibitive for growth. Interestingly, the 
addition of L-Met into M9 media restored the 
growth of all these mutant strains, consistent with 
the presence and activity of the putative and 
functional low-affinity transporter ‘MetP’ (19,20). 
Hence, this data supports the theory that MetP 
activity enables sufficient Met uptake to facilitate 
efficient growth in vitro.  
To determine whether the observed in vitro 
growth attenuation was reflected by reduced 
growth of S. Typhimurium inside mammalian cells, 
∆metNIQ, ∆metNIQ∆metB and ∆metNIQ∆metEH 
mutants were used to infect HeLa cells in Met-free 
DMEM. Whereas ∆metNIQ mutant was capable of 
intracellular growth to a level similar to SL1344 
over a 10-hour period, ∆metNIQ∆metB and 
∆metNIQ∆metEH mutants were unable to grow 
(Fig. 3C, top row). The presence of L-Met in 
DMEM fully restored the growth of the mutant 
strains in HeLa cells (Fig. 3C, bottom row), 
suggesting that the activity of the cryptic 
transporter MetP was sufficient to support 
intracellular growth in HeLa cells. 
To determine whether dual mutations in de 
novo biosynthesis and high-affinity transporter of 
Met reduced S. Typhimurium virulence in vivo, 
C57BL/6 mice were intravenously infected with 
∆metNIQ, ∆metNIQ∆metB and ∆metNIQ∆metEH 
mutant strains or whild-type. At day 5 post-
infection, mice infected with ∆metNIQ had a 
similarly high bacterial load in the liver (Fig. 3D) 
and spleen (Fig. 3E) and comparable with that of 
SL1344-infected mice, indicating that loss of the 
high-affinity Met transporter alone does not reduce 
S. Typhimurium virulence in vivo. In contrast, 
infection with ∆metNIQ∆metB and 
∆metNIQ∆metEH mutants resulted in a 
significantly reduced bacterial load in the liver (Fig. 
3D) and spleen (Fig. 3E), and this attenuation was 
reversed when the ∆metNIQ∆metB mutant was 
complemented by metB (Fig. 3D and E). Similar 
results were obtained when the ∆metNIQ∆metB 
and ∆metNIQ∆metEH mutants were used to infect 
mice via the oral route (Supplementary Fig. S4), 
confirming that ∆metNIQ∆metB and 
∆metNIQ∆metEH are attenuated in mice regardless 
of the route of infection. Taken together, these 
results demonstrate that restriction of Met 
availability has a strong impact on the virulence of 
S. Typhimurium in vivo, and the presence of the 
putative cryptic transporter (MetP) alone is 
insufficient to sustain maximal bacterial growth in 
the permissive murine host. 
 
Metabolite profiling in S. Typhimurium Met 
biosynthetic and high-affinity transporter mutants  
To further define the impact of Met 
pathway gene disruptions on bacterial metabolism, 
S. Typhimurium wild-type and mutants lacking 
either or both of the de novo biosynthesis pathway 
and the high-affinity Met transporter were grown in 
LB media, and polar metabolites were extracted 
and analysed by liquid chromatography-mass 
spectrometry (LC-MS). The intracellular 
accumulation of 5-methyl-tetrahydropteroyltri-L-
glutamate, a member of the polyglutamate forms of 
5-methyltetrahydrofolate (37), was significantly 
increased in ∆metH (~10 fold) and further increased 
in ∆metNIQ∆metEH (~25 fold), but not in ∆metE, 
compared with SL1344 (Fig. 4). This result 
suggests that both MetE and MetH are functionally 
active as S. Typhimurium grew in LB broth, but 
MetH is either more abundant, or more efficient in 
the formation of 5-methyltetrahydrofolate. On the 
other hand, the ∆metB mutant exhibited a 
significantly elevated pool of O-
succinylhomoserine compared to the wild-type, 
consistent with a defect in the MetB catalysed 
conversion of O-succinylhomoserine to 
cystathionine (Fig. 4).  
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An untargeted mass/charge (m/z) feature 
analysis of the mutant lines led to the identification 
of a number of unexpected metabolite changes. 
Pair-wise comparisons were performed to identify 
differences that were statistically different (p<0.05) 
and to filter interesting m/z features. Deletion of 
metB led to significant increases in the intracellular 
levels of SAM (5.5-fold increase compared to wild-
type), and a number of other metabolites including 
glycerate, adenine, hexose-6-phosphate, 3-
phosphoglycerate and gluconate were also 
increased compared to the wild-type (Fig. 5A and 
Table 3). By comparison, ∆metE did not show any 
significantly different m/z features (Fig. 5B) 
whereas only the m/z feature corresponding to 5-
methyl-tetrahydropteroyltri-L-glutamate, a 
representative form of 5-methyltetrahydrofolate, 
was significantly different in the ∆metH mutant 
(Fig. 5C).  
Interestingly, several m/z features 
corresponding to peptidoglycan biosynthetic 
intermediates were significantly different for the 
∆metB mutant, including UDP-N-acetyl-
muraminate-alanine-glutamate (Fig. 5D). This, in 
turn, suggested an association between Met 
biosynthesis and peptidoglycan biosynthesis. 
Disruption of metB led to a decrease in intracellular 
concentrations of UDP-N-acetyl-muraminate 
(~0.4-fold) and a large increase of UDP-N-acetyl-
muramoyl-L-alanine (12-fold), UDP-N-acetyl-
muramoyl-L-alanyl-D-glutamate (1400-fold) and 
UDP-N-acetyl-muramoyl-L-alanyl-D-γ-glutamyl-
meso-2,6-diaminopimelate (4-fold) (Fig. 5D). A 
decrease in UDP-N-acetyl-muraminate and an 
increase in UDP-N-acetyl-muramoyl-L-alanine (9-
fold), UDP-N-acetyl-muramoyl-L-alanyl-D-
glutamate (1000-fold) and UDP-N-acetyl-
muramoyl-L-alanyl-D-γ-glutamyl-meso-2,6-
diaminopimelate (5-fold) was also observed in the 
double mutant ∆metNIQ∆metB (Fig. 5D). 
Ex vivo, the ∆metB mutant had a reduced 
growth rate compared with the wild-type in bile 
salts. To study the impact of the altered levels of 
peptidoglycan-related metabolites, the ∆metB 
mutant and wild-type were tested in LB broth in the 
presence of EDTA, SDS, lysozyme, fasted state 
simulated intestinal fluid (FaSSIF), but no 
significant differences in growth were found 
(Supplementary Table S1). A small increase (~2 
mm on 15 mm) in β-lactam antibiotic sensitivity, 
using a validated disc sensitivity method, was 
observed for the ∆metB mutant (data not shown). In 
addition, when the ∆metB and wild-type were 
tested in MacConkey broth supplemented with 
0.6% bile salt a small but consistent delay in the 
growth of ∆metB was observed (Supplementary 
Figure S5). 
 
Discussion 
There is increased interest in identifying 
metabolic pathways in bacterial pathogens, which 
are essential and distinct from those in their 
mammalian and human hosts, as potential antibiotic 
targets (38-42). Previous studies suggested that 
perhaps 400 S. enterica enzymes are dispensable 
and that essential pathways are often protected 
against random mutation by redundancy, reflecting 
the selective pressure placed on metabolism as a 
key virulence trait (13). Met biosynthesis and 
transport is an important part of the interconnected 
and interdependent amino acid metabolism (43). In 
this study, the essentiality of Met biosynthesis and 
transport in the mammalian virulence of S. 
Typhimurium was investigated.  
We showed that de novo Met biosynthesis 
is not essential when the bacteria are able to obtain 
Met from their environment. The growth rate of the 
bacteria with or without de novo Met biosynthesis 
appeared similar in Met-rich media (e.g. LB broth), 
suggesting that transport systems can compensate 
for the loss of de novo biosynthesis. Met 
biosynthetic mutants requires the presence of Met 
in the culture media in order to grow inside of HeLa 
cells (Fig. 2D and Supplementary Fig. S2), 
suggesting that extracellular Met becomes available 
to bacteria in the SCV within a few hours of 
infection. It is likely that Met is relatively abundant 
in the SCV during in vivo infection, as all of the Met 
biosynthetic mutants were as virulent as wild-type 
S. Typhimurium in mice (Fig. 2E and F), 
presumably because the Met acquisition systems 
have access to a sufficient source of Met for 
supporting bacterial growth in the infected animal. 
It is only when de novo biosynthesis and 
high-affinity transport of Met are both disrupted 
that we observed severe growth attenuation in HeLa 
cells (Fig. 3C) and importantly, in infected mice 
(Fig. 3D and E). This result strongly suggests 
functional redundancy between transport and 
biosynthesis as a source of Met for S. Typhimurium 
inside of the host. Whether Met is acquired (e.g. 
∆metB) or synthesised (e.g. ∆metNIQ∆metB and 
∆metNIQ∆metB complemented with metB), the 
growth in vivo appears to be comparable, 
suggesting that either de novo biosynthesis or the 
high-affinity transport system of Met alone can 
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provide Met in excess to what is required for S. 
Typhimurium to grow at maximal capacity in the 
host. Hence, at least in the case of S. Typhimurium, 
it is probably quite difficult to inhibit growth by 
targeting the Met biosynthetic pathway. The 
observation that ∆metNIQ∆metB and 
∆metNIQ∆metEH were still able to grow in mice is 
suggestive of a Met acquisition system independent 
of MetNIQ, which is consistent with the presence 
of a low-affinity transporter MetP (19,20). Hence, 
our study also provides additional support for the 
presence of a putative, low-affinity transporter 
‘MetP’, which has yet to be identified.  
Our description of this apparent 
redundancy between de novo synthesis and high-
affinity transport of Met conflicted with previous 
studies that showed Met auxotrophs are defective 
for intracellular survival in macrophages and 
epithelial cells (22,23), and have reduced virulence 
in mice (24,28) and in 1-day old chickens (34). This 
may be at least in part due to differences in the 
study design. In our study, C57BL/6 mice were 
infected with a single strain; whereas previous 
studies typically using competition assays (i.e. 
infecting the same host with wild-type and mutant 
strains), which may put more pressure on the 
mutant to grow in the competitive environment. It 
is not uncommon to have divergent results from 
single infections and competitive infections 
(44,45). Another study has shown that the S. 
Typhimurium lacking the high-affinity transporter 
MetNIQ is attenuated in C3H/HeN mice (25). 
C3H/HeN mice carry the resistant allele of 
Nramp1, which controls Fe3+ availability in the 
phagosome and is a major determinant of murine 
susceptibility to S. Typhimurium; consequently 
C3H/HeN mice are much more resistant to S. 
Typhimurium infection than the Nramp1 deficient 
C57BL/6 mice (46,47). It is possible that the 
differences in attenuation observed in earlier 
studies, but not ours, relate to differences in genetic 
susceptibility of the mice. Finally, earlier animal 
studies did not complement the bacterial Met 
mutation, nor sequence the mutant strains, and it is 
possible that secondary mutations, not mutations in 
Met biosynthesis per se, were responsible for the 
observed attenuation in mice. 
To generate novel insights about the Met 
biosynthesis pathway in S. Typhimurium, the 
changes in bacterial concentrations of key 
metabolites was examined by LC-MS (Fig. 4 and 
5). Mass spectrometry revealed substrate 
accumulation in Met biosynthetic mutants ∆metB, 
∆metE, ∆metH and the high-affinity transporter 
mutant ∆metNIQ, and mutants deficient in both 
(∆metNIQ∆metB and ∆metNIQ∆metEH). This 
analysis revalidated the pathway model for Met 
biosynthesis shown in Fig. 1, which has been 
proposed since the 1980s but to the best of our 
knowledge, has not been systematically studied in 
S. enterica until now.  
The observed accumulation of substrates 
provides interesting insights into the kinetics of 
enzyme activities. The deletion of both Met 
synthases (i.e. ∆metNIQ∆metEH) leads to a 
profound difference in 5-methyltetrahydrofolate 
concentration, a metabolite in the one-carbon cycle 
(Fig. 4). In the ∆metH mutant, there is a 10-fold 
higher intracellular concentration of the substrate 
compared to ∆metE, indicating that MetE is much 
less efficient than MetH, supporting previous 
findings (48). Presumably, perturbation of the one-
carbon cycle led to an accumulation of 
homocysteine, which is toxic for bacterial cells 
(49,50). This is probably why we consistently 
observed that ∆metNIQ∆metEH grew slower in 
vivo compared to ∆metNIQ∆metB (Fig. 3, 
Supplementary Fig. S4). 
The disruption of the metB gene led to 
several unexpected observations. Firstly, the 
intracellular pool of SAM was increased in ∆metB 
compared with wild-type (Fig. 4), indicating a 
defect in SAM catabolism following perturbation 
of the activated methyl cycle in this mutant. This 
observation argues that, in the ∆metB mutant, 
homocysteine, which is converted into SAM, 
cannot be derived through de novo biosynthesis in 
∆metB, hence is not fed into the activated methyl 
cycle. Further comparisons of the LC-MS/MS data 
between ∆metB and SL1344 revealed differences in 
many metabolites from disparate pathways; how 
disruption to a single enzyme in Met biosynthesis 
caused perturbations in other pathways was unclear 
but the data demonstrates the complexity of 
modelling intracellular metabolite fluxes in 
bacteria. Interestingly, this analysis revealed that 
the concentration of several metabolites linked with 
peptidoglycan synthesis, were grossly increased in 
∆metB and ∆metNIQ∆metB (Fig. 5D). 
Enterobacteriaceae peptidoglycan usually consists 
of alternating molecules of N-acetyl-glucosamine 
and N-acetyl-muramic acid that are linked by a 
tetrapeptide of L-alanine, D-glutamate, 
diaminopimelic acid (DAP) and D-alanine. 
Because Met biosynthesis and m-DAP biosynthesis 
are linked through aspartate metabolism (43), and 
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L-cystathionine can substitute for DAP (51), the 
perturbation of the intracellular metabolite pools 
related to Met biosynthesis might also impact 
peptidoglycan synthesis. While LC-MS revealed 
significant changes in the levels of peptidoglycan 
intermediates, these changes were not reflected by 
increased sensitivity to agents, e.g. β-lactam 
antibiotics, which act through peptidoglycan 
synthesis, or directly on peptidoglycan, with the 
exception of growth in bile. Bile is known to 
remodel S. enterica peptidoglycan (52). However, 
it is recognised that Enterobacteriaceae with 
altered cell wall physiology are very robust. For 
example, E. coli with decreased m-DAP, which 
reduced the peptidoglycan density by 50%, did not 
show any detectable alteration in morphology or 
growth characteristics (53).  
The data obtained from the LC-MS 
analysis with the complemented mutant 
∆metNIQ∆metB (Fig. 4 and 5) suggested that 
complementation by pACYC184metB did not fully 
restore the metabolite levels seen in the ∆metNIQ 
mutant. However, this is not unusual since, as 
related, genetic complementation using a plasmid 
will differ from the native level due to plasmid copy 
number and regulation, accounting for the partially 
complemented phenomena that is observed. 
This study supports earlier models of S. 
enterica metabolism that have suggested significant 
redundancy in key pathways linked with growth 
(13). The research reported here was a systematic 
analysis of Met metabolism in response to earlier 
investigations, which suggested that Met 
auxotrophy was attenuating for bacterial growth in 
animals, and that de novo Met metabolism might 
therefore provide new antibiotic targets. The 
regulation of Met synthesis, a complex regulon 
comprising MetR and MetJ (16,54), was not 
investigated since the aim of the study was to 
determine the essentiality of de novo Met synthesis 
in in vivo growth. We found that mutants unable to 
synthesise Met efficiently obtained the amino acid 
from their intracellular niche via their high-affinity 
Met transporter, suggesting that the SCV contains 
sufficient Met to sustain normal bacterial growth 
even in the absence of de novo synthesis. Severe 
reductions in virulence in vivo was only observed 
when both de novo Met biosynthesis and high-
affinity Met transport were lost. The impact of 
mutations in the Met biosynthesis and transporter 
genes on other pathways was revealed, reaffirming 
the complexity of the bacterial metabolome and the 
interactions between metabolites that have yet to be 
mapped. Considerably more basic science on 
bacterial metabolism will be needed to identify 
novel, functionally non-redundant targets. 
 
Experimental procedures 
Bacterial strains and growth conditions 
The bacterial strains and plasmids used in 
this study are listed in Table 1. All mutant strains 
were constructed on the S. Typhimurium SL1344 
genetic background and SL1344 was used as the 
wild-type strain in all experiments. The SL1344 
strain has been described previously (36); its 
virulence is well defined and is resistant to 
streptomycin. Appropriate antibiotics, including 
streptomycin (50 µg/ml) chloramphenicol (30 
µg/ml), kanamycin (50 µg/ml) and ampicillin (100 
µg/ml) were added to growth media as required. To 
obtain mid-exponential growth phase, S. 
Typhimurium and E. coli strains were grown in 10 
ml Luria-Bertani (LB) broth (BD Difco) overnight, 
and 100 µl of the overnight culture was subcultured 
into 10 ml fresh LB broth, and grown with shaking 
(180 rpm) at 37ºC for 3-4 hours until the optical 
density reading at 600 nm reached 0.6-0.8. Growth 
phenotypes were characterised in LB broth or M9 
minimal media (2 mM MgSO4, 0.1 mM CaCl2, 
0.4% glucose, 8.5 mM NaCl, 42 mM Na2HPO4, 22 
mM KH2PO4, 18.6 mM NH4Cl and 100 µM 
histidine). Met or vitamin B12 was supplemented at 
100 µM. For assessing growth under anaerobic 
conditions, cultures were grown shaking in air-tight 
jars with AnaeroGen (ThermoFisher) for depletion 
of oxygen.  
Construction of strains and plasmids 
Defined deletions of sequence encoding the 
met biosynthesis genes metA, metB, metC, metE, 
metF, metH and Met high-affinity transporter 
metNIQ were generated in S. Typhimurium 
SL1344. The biosynthetic mutant and high-affinity 
transporter mutant were combined together to 
generate the double mutant ∆metNIQ∆metB and the 
triple mutant ∆metNIQ∆metEH. The double mutant 
∆metNIQ∆metB was complemented by introducing 
the de novo biosynthetic metB gene into 
∆metNIQ∆metB strain in trans. This strain is 
named as ∆metNIQ∆metB pACYC184metB. Gene 
deletions and concomitant insertions of an 
antibiotic resistance cassette were constructed 
using a Lambda Red-mediated ‘gene gorging’ 
method (55). All constructs were verified by PCR 
and moved to a SL1344 or relevant background via 
P22 phage transduction (36,56). Primers used to 
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construct mutants are listed in Table 2. Genetic 
complementation of mutant ∆metNIQ∆metB was 
achieved by cloning metB into pACYC184 via the 
BamHI and SalI sites and then introducing 
pACYC184metB into the ∆metNIQ∆metB mutant. 
All constructs were verified by restriction analysis 
and DNA sequencing. Key mutants were also 
sequenced using Illumina whole genome 
sequencing and analysed using the pipeline at the 
Wellcome Sanger Institute, Hinxton, UK. 
 
Infection of epithelial cells 
Infection of HeLa cells (sourced from 
American Type Culture Collection (ATCC)) was 
conducted using established gentamicin protection 
assay protocols (57,58). Briefly, HeLa cells were 
grown in DMEM supplemented with 10% fetal calf 
serum (FCS) and 2 mM L-glutamax (Life 
Technologies), in a humidified 37°C, 5% CO2 
incubator. One day prior to infection, HeLa cells 
were seeded in 24-well plates at 2×105 cells per 
well. S. Typhimurium strains were grown to mid-
exponential phase prior and frozen in LB with 10% 
glycerol at -80°C. Bacteria were thawed 
immediately before infection, washed in antibiotic-
free tissue culture media and diluted in DMEM 
media with or without L-Met, then added to HeLa 
cell monolayers at a multiplicity of infection (MOI) 
of 5-10. The cfu in the inoculum was estimated by 
plating on LB agar plates. Infected HeLa cells were 
centrifuged at 600 × g for 5 min immediately after 
the addition of bacteria and then incubated for 1 
hour at 37°C. After 1 hour, the tissue culture media 
was replaced with DMEM media with or without 
Met and containing 100 µg/ml of gentamicin to kill 
extracellular bacteria. The concentration of 
gentamicin was reduced to 10 µg/ml at 2 hours 
post-infection and maintained for the remainder of 
the experiment. To enumerate intracellular bacteria, 
cells were washed twice with PBS, and lysed with 
1% Triton X-100 (Sigma) for 15 min to release the 
intracellular bacteria. The bacteria were 
enumerated by plating appropriate dilutions on LB 
agar plates. 
 
Ethics Statement 
All animal research conducted in this study 
was approved by the Animal Ethics Committee 
(Biochemistry & Molecular Biology, Dental 
Science, Medicine, Microbiology & Immunology) 
at The University of Melbourne, under project 
number 1413141. All experiments were conducted 
in accordance with the Australian Code of Practice 
for the Care and Use of Animals for Scientific 
Purposes, 8th edition 2013. 
 
Mouse infections 
Age- and sex-matched C57BL/6 mice were 
used between 6-8 weeks of age, to assess the 
virulence of mutant strains, using either the 
intravenous or oral route of infection. For 
intravenous infections, 200 cfu of each bacterial 
strain was prepared in 200 µl PBS and injected into 
the lateral tail vein. For oral infections, mice were 
orally gavaged with 100 µl 10% sodium 
bicarbonate immediately before oral gavage of 200 
µl containing approximately 5×107 cfu of S. 
Typhimurium strains. To prepare the inoculum, all 
strains of S. Typhimurium were grown shaking at 
180 rpm in M9 minimal media supplemented with 
100 µM Met, at 37ºC for 24 hours, and stored in 
10% glycerol at -80ºC until use. Immediately prior 
to infection, the stored aliquots were thawed and 
diluted in PBS to the required concentration. At 
designated time points post-infection, the spleen 
and liver were removed aseptically, homogenated 
using the Stomacher 80 Biomaster paddle blender 
(Seward), and serial dilutions were plated on LB 
agar plates with streptomycin to determine the 
bacterial load.  
 
Preparation of stock solutions and standards for 
Liquid Chromatography-Mass Spectrometry (LC-
MS) 
Stock solutions of the related underivatized 
metabolites were prepared at 1.0 mg/ml in an 
appropriate solvent. Before using, the solutions 
were combined and diluted with water to give an 
appropriate standard metabolite mix solution. 
13C15N-Aspartate (Cambridge Bioscience) was 
used as an Internal Standard at 1 µM in Milli-Q 
water. All stock solutions were stored at -20ºC. 
 
Sample harvest (metabolic arrest) for LC-MS 
Each S. Typhimurium strain was grown at 
37°C to mid-exponential phase in 10 ml LB, with 
shaking at 180 rpm. The culture was diluted into 30 
ml PBS, and chilled in an ice/water slurry for 5 min 
and subsequently centrifuged (931 ×g, 1ºC, 10 
min). The pellet was then washed in 1 ml PBS and 
centrifuged (17,295 × g). This washing step was 
repeated before removing the PBS and storing the 
cell pellet at -80ºC until metabolite extraction was 
performed.  
 
Extraction of metabolites for LC-MS 
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Cell pellets were resuspended with 400 µl 
of 75% ethanol solution containing 1:1000 of 
Internal Standard. Cell lysis was ensured by 
repeated cycles of freeze-thaw, for a total of 10 
times, while cooling to -80ºC. Cellular debris was 
pelleted by centrifugation (17,295 × g, 5 min, 1ºC). 
The metabolic extract was transferred to a new tube 
and stored at -80ºC until analysis. 
 
Instrumentation 
A SeQuant ZIC-pHILIC column (5 µM, 
150 × 4.6 mm, Millipore) coupled to a 1260 series 
HPLC system (Agilent) was used to separate 
metabolites. The method used was previously 
described (59) with slight modifications: a flow rate 
of 0.3 mL/min with 20 mM ammonium carbonate 
in water and 100% acetonitrile was used as the 
mobile phase. A binary gradient was set up as 
follows: 0.5 min: 80% acetonitrile, 15.5 min: 50% 
acetonitrile, 17.5 min: 20% acetonitrile, 18.5 min: 
5% acetonitrile, 21 min 5% acetonitrile, 23 min 
80% acetonitrile and held at 80% acetonitrile until 
29.5 min. Detection of metabolites was performed 
on an Agilent Q-TOF mass spectrometer 6545 
operating in negative ESI mode. The scan range 
was 85-1200 m/z between 2 and 28.2 min at 0.8 
spectra/sec. 
 
Calibration and validation 
LC-MS.d files were converted to .mzXML 
files using MS convert and analysed using the 
LCMS R package (60,61). Following alignment, 
groups were extracted with a mass window of 10 
ppm and statistical analysis performed using 
MetaboAnalyst 3.0 (62). The dataset was uploaded, 
filtered using the interquartile range, log 
transformed, and a one-way ANOVA performed 
with Tukey’s HSD (p < 0.01). Data was analysed 
using MAVEN in parallel to validate the LCMS 
results (63). Following alignment, metabolites were 
assigned using exact mass (<10 ppm) and retention 
time (compared to a standards library of 150 
compounds run the same day). Scatter plots were 
generated for each pairwise comparison and 
statistical significance was determined using a P 
value < 0.05 with Benjamini correction. 
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Table 1. Strains and plasmids used for this study. 
 
Strain or plasmid Relevant phenotypes and genotypes Source 
Strains  
Salmonella enterica Typhimurium SL1344 Wild-type strain rpsL hisG46; StrR (36) 
Salmonella enterica Typhimurium BRD666  
Restriction negative modification 
positive (r-m+) SL1344; StrR 
(68) 
Escherichia coli DH5α Cloning strain  (69) 
Plasmids  
pGEM-T Easy  
High-copy-no. cloning vector for PCR 
products; ApR 
Promega 
pACBSR 
Medium-copy number, mutagenesis 
plasmid; p15A ori; Ara-inducible I-
SceI and λ Red recombinase; ChlR 
(55) 
pACYC184 
Medium-copy number cloning vector, 
p15A ori; TetR, ChlR 
(70) 
pACYC184metB 
S. Typhimurium SL1344 metB cloned 
into pACYC184; ChlR 
This 
study 
pCP20  
FLP recombinase, temperature-
sensitive replicon; ApR, ChlR 
 
(71) 
pKD4 FRT-flanked KmR cassette; ApR, KmR (72) 
Str, streptomycin; Ap, ampicillin; Chl, chloramphenicol; Km. kanamycin; Ara, arabinose; Flp, flippase; 
FRT, fippase recombinase target. 
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Table 2. Oligonucleotide primers used in this study for construction of mutants and 
complementation. 
 
Mutants Sequence (5’-3’) 
∆metA-ISceI-F TAGGGATAACAGGGTAATCGCCAGTGTTAACGCATGTTC 
∆metA-ISceI-R TAGGGATAACAGGGTAATCGGAATACCACGAATCTGCC 
∆metA-Kan-F CTAAGGAGGATATTCATATGCGCAGCCACGGTAATTTACTG 
∆metA-Kan-R GAAGCAGCTCCAGCCTACACAACCTGATAACCTCACGACATACG 
∆metB-ISceI-F TAGGGATAACAGGGTAATCGCAGATCGGCATCATCC 
∆metB-ISceI-R TAGGGATAACAGGGTAATCTTCATCAACCTGCGGCTG 
∆metB-Kan-F CTAAGGAGGATATTCATATGCGGTATTGAAGATGGCGAAG 
∆metB-Kan-R GAAGCAGCTCCAGCCTACACACAGCCGTATTGTTCGTCATCG 
∆metC-ISceI-F TAGGGATAACAGGGTAATCCTTCGTTATCTTCGCTGCC 
∆metC-ISceI-R TAGGGATAACAGGGTAATCAGCAGAGTGCGGACAAACG 
∆metC-Kan-F CTAAGGAGGATATTCATATGGCTGGTTCGGGTGCATATTG 
∆metC-Kan-R GAAGCAGCTCCAGCCTACACACACTATTCACTGAGCCAAGCG 
∆metE-ISceI-F TAGGGATAACAGGGTAATCTACCTGCGGCCAGCTTG 
∆metE-ISceI-R TAGGGATAACAGGGTAATCAATGCGGTCGCCACTCTG 
∆metE-Kan-F CTAAGGAGGATATTCATATGGGCGTTAGCGAACATGGTC 
∆metE-Kan-R GAAGCAGCTCCAGCCTACACATCAACTCGCGACGCAGG 
∆metF-ISceI-F TAGGGATAACAGGGTAATGCAGCCTGATGGAGCATGG 
∆metF-SceI-R TAGGGATAACAGGGTAATGCCACGACCATCAATAGAACG 
∆metF-Kan-F CTAAGGAGGATATTCATATGGCCGTGAAGGAGTGAAGGA 
∆metF-Kan-R GAAGCAGCTCCAGCCTACACACTTCCGCCAGGCTCTGATTC 
∆metH-ISceI-F TAGGGATAACAGGGTAATCGGTGAGTCGTGGAATTAGGC 
∆metH-ISceI-R TAGGGATAACAGGGTAATCGTCAGGGCGACAAGATCC 
∆metH-Kan-F CTAAGGAGGATATTCATATGGAGGATGTTGAGCGGTGGC 
∆metH-Kan-R GAAGCAGCTCCAGCCTACACAGCCGTCCAGCACCAGAATAC 
∆metNIQ-ISceI-F TAGGGATAACAGGGTAATCACAGCTGTGCAGCAGG 
∆metNIQ-ISce-R TAGGGATAACAGGGTAATACTGCCCTGCGGATGG 
∆metNIQ-Kan-F CTAAGGAGGATATTCATATGTCCCCTGCTGGAACACTT  
∆metNIQ-Kan-R GAAGCAGCTCCAGCCTACACAGTCTGATGAAGTGTACGAAGCC 
metB-BamHI-F TGGATCCGTCGCAGATGTGCGCTAATG  
metB-SalI-R TGTCGACCATAATGCCTGCGACACGC 
Endonuclease restriction sites are underlined; kanamycin resistance cassette-specific sequences are in bold; 
F, forward (5’) primer; R, reverse (3’) primer.  
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Table 3. List of metabolites with significantly changes in ∆metB mutant compared to wild-type.  
 
XCMS ID Metabolite name m/z 
Fold change 
(∆metB to WT) 
p-value FDR 
M900T1200 4-Hydroxyphenylacetyl-CoA 900.15 3247.21 4.17E-07 4.01E-05 
M878T1201 
UDP-N-acetylmuramoyl-L-alanyl-D-
glutamate 
878.17 1646.67 7.63E-08 1.45E-05 
M880T1200 3-Hydroxyhexanoyl CoA 880.18 220.30 6.08E-07 5.15E-05 
M749T1087 UDP-N-acetylmuramoyl-L-alanine 749.13 12.24 7.22E-06 2.49E-04 
M163T480 Rhamnose 163.06 10.30 3.99E-08 1.33E-05 
M275T1210 6-Phosphogluconate 275.02 8.93 1.01E-04 1.74E-03 
M105T825 D-Glycerate 105.02 8.15 8.18E-06 2.67E-04 
M259T1165 Hexose-Phosphate 259.02 7.36 7.32E-04 8.43E-03 
M266T579 Adenosine 266.09 6.13 1.44E-04 2.33E-03 
M195T999 Gluconate 195.05 6.13 7.04E-07 5.68E-05 
M1050T1225 
UDP-N-acetylmuramoyl-L-alanyl-D-γ-
glutamyl-meso-2,6- diaminopimelate 
1050.26 5.63 1.75E-06 9.97E-05 
M189T1246 Diaminoheptandioate 189.09 4.73 6.05E-07 5.15E-05 
M620T1224 
UDP-N-acetyl-2-amino-2-deoxy-D-
glucuronate 
620.05 4.67 9.09E-09 7.57E-06 
M134T607 Adenine 134.05 4.44 6.48E-06 2.31E-04 
M686T707 Dephospho-CoA 686.14 4.22 1.36E-05 3.75E-04 
M218T1006 O-Succinyl-L-homoserine 218.07 3.75 5.85E-05 1.14E-03 
M145T567 2-Dehydropantoate 145.05 3.72 2.60E-05 6.15E-04 
M130T567 hydoxy-proline 130.05 3.19 2.46E-04 3.57E-03 
M273T1080 Succinyl-Arginine 273.12 2.55 1.28E-04 2.11E-03 
M678T1139 UDP-N-acetylmuraminate 678.09 2.45 1.41E-07 2.10E-05 
M227T987 4-Phosphopantoate 227.03 2.11 3.55E-04 4.74E-03 
M116T860 Valine 116.07 2.03 1.21E-04 2.02E-03 
This table presents results from a one-way ANOVA performed with Tukey’s honest significant difference 
(HSD) tests (p<0.01). FDR, false discovery rate. 
 
 
  
 at L
O
N
D
O
N
 S
C
H
 O
F
 H
Y
G
IE
N
E
 &
 T
R
O
P
IC
A
L
 M
E
D
IC
IN
E
 o
n
 M
ay
 4
, 2
0
1
8
h
ttp
://w
w
w
.jb
c.o
rg
/
D
o
w
n
lo
ad
ed
 fro
m
 
Methionine in Salmonella Typhimurium virulence!
!
 18 
Figure legends 
 
Figure 1. Schematic diagram of the biosynthetic pathway of Met in S. Typhimurium. The first 
committed step of the pathway is catalysed by homoserine transsuccinylase (MetA), which succinylates 
homoserine to form O-succinyl L-homoserine, which then undergoes a condensation reaction with cysteine 
to form L-cystathionine, catalysed by cystathionine γ-synthase (MetB). Cystathionine β-lyase (MetC) 
catalyses the conversion of L-cystathionine to L-homocysteine, pyruvate and ammonia. The final 
biosynthetic step is catalysed by distinct Met synthases, MetH and MetE, which are vitamin B12-dependent 
and -independent synthases, respectively (31,32,64). In this final step, L-homocysteine is condensed with 
5,10-methyltetrahydrofolate (CH3H4Folate), which donates the methyl group. CH3H4Folate is provided 
from the one-carbon cycle through a methylenetetrahydrofolate reductase (MetF)-mediated reaction, 
producing tetrahydrofolate (H4Folate) and Met (65). In S. enterica, Met is recycled through an activated 
methyl cycle. The primary methyl donor S-adenosyl methionine (SAM) is formed by the activation of Met 
through an ATP-dependent condensation reaction catalyzed by the S-adenosyl methionine synthase 
(MetK)(2,66,67). Catalytic enzymes are in red; arrows indicate the direction of catalytic reactions. 
 
Figure 2. The de novo biosynthetic mutants demonstrate Met-dependent growth in M9 minimal 
media and in HeLa cells, but remain fully virulent in mice. S. Typhimurium wild-type (WT) SL1344 
and mutant strains were grown shaking at 37°C in M9 minimal media with or without A) Met, B) vitamin 
B12, or C) oxygen, and the number of viable bacteria (cfu) was determined after 24 hours. Bars represent 
the mean cfu and error bars show the data range. Dotted lines represent the bacterial concentration at the 
time of inoculation. Data are pooled from two independent experiments. D) The de novo Met biosynthetic 
mutants become defective for intracellular replication in HeLa cells when Met is absent in the DMEM 
media. HeLa cells were grown to a monolayer and infected with S. Typhimurium WT or mutant strains at 
a multiplicity of infection (MOI) of 5-10, in Met-free DMEM. The intracellular bacterial load at 2 hours 
post-infection is expressed as “1” and used as the reference point to calculate fold-change of intracellular 
bacterial number at subsequent time points. Data are pooled from three independent experiments. Bars 
represent the mean cfu and error bars show the data range. Unpaired t-tests were used to compare the 
intracellular load of WT and mutant strains at 10 hours post-infection, and p-values shown were corrected 
for multiple comparisons using the Bonferroni-Dunn method; p-values greater than 0.05 were deemed as 
not significant (ns). For assessing virulence in vivo, age- and sex-matched C57BL/6 mice were 
intravenously infected with 200 cfu of indicated strains of S. Typhimurium, and the bacterial load in the E) 
liver and F) spleen was determined at day 5 post-infection. Symbols represent data from individual animals, 
and horizontal lines represent the geometric mean of each group. Data are pooled from two independent 
experiments. One-way ANOVA with Bonferroni post-tests was used for statistical analyses comparing each 
pair of data groups, and none of the comparisons yielded a p-value below 0.05.  
 
Figure 3. S. Typhimurium mutants deficient in the de novo biosynthesis and high-affinity transport 
of Met are highly attenuated in mice. A) S. Typhimurium strains were grown shaking at 37°C in M9 
minimal media with or without Met, and the number of viable bacteria (cfu) was determined after 24 hours. 
Bars represent the mean cfu and error bars show the data range. Dotted lines represent the bacterial 
concentration at the time of inoculation. Data are pooled from two independent experiments. B) HeLa cells 
were grown to a monolayer and infected with S. Typhimurium WT or mutant strains at a multiplicity of 
infection (MOI) of 5-10, in DMEM media with or without Met. The intracellular bacterial load at 2 hours 
post-infection is expressed as “1” and used as the reference point to calculate fold-change of intracellular 
bacterial number at subsequent time points. Bars represent the mean cfu and error bars show the data range. 
Data are pooled from three independent experiments. Unpaired t-tests were used to compare the 
intracellular load of WT and mutant strains at 10 hours post-infection, and p-values shown were corrected 
for multiple comparisons using the Bonferroni-Dunn method; p-values greater than 0.05 were deemed as 
not significant (ns). For assessing virulence in vivo, age- and sex-matched C57BL/6 mice were 
intravenously infected with 200cfu of indicated strains of S. Typhimurium, and the bacterial load in the D) 
liver and E) spleen was determined at day 5 post-infection. ∆metNIQ∆metB/pmetB-c’ denotes the 
complemented strain ∆metNIQ∆metB pACYC184metB. Symbols represent data from individual animals, 
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and horizontal lines represent the geometric mean of each group. Data are pooled from three independent 
experiments. One-way ANOVA with Bonferroni post-tests was used for statistical analyses, ****, 
p<0.0001; ns, p>0.05. 
 
Figure 4. Metabolite perturbations following genetic disruption to Met biosynthesis, one-carbon cycle 
and activated methyl cycle. Total metabolite pools in each strain were detected and quantitated using LC-
QTOF (Liquid Chromatography-Quadrupole Time-of-flight). Key intermediates of the Met biosynthetic 
pathway, activated methyl cycle and one-carbon cycle were identified and quantified for the indicated S. 
Typhimurium strains, and compared to the wild-type level; fold-changes are shown for A) 5-
methyltetrahydropteroyltri-L-glutamate, a member of the polyglutamate forms of 5-methyltetrahydrofolate, 
B) O-succinyl homoserine, C) Met and D) SAM. ∆metNIQ∆metB/pmetB-c’ denotes the complemented 
strain ∆metNIQ∆metB pACYC184metB. Individual data points represent biological replicates, and the 
mean for each group is shown. One-way ANOVA with Bonferroni post-tests were used to compare the 
metabolite level in each mutant to wild-type, p-values <0.05 are shown: *, p<0.05; **, p<0.01; ***, 
p<0.001; and ****, p<0.0001. 
 
Figure 5. Metabolite perturbations following genetic disruption to metB, metE and metH. Scatter plots 
depict wild-type compared to A) ∆metB, B) ∆metE and C) ∆metH. Each dot represents a single extracted 
m/z feature with each axis depicting the arbitrary ion count. m/z features which are no different between 
conditions plot along the diagonal. The colour intensity indicates the confidence of the difference (greater 
intensity equates to lower variance across biological replicates). Yellow highlight indicates a subset of 
confirmed metabolites with a statistically significant difference in a pair-wise comparison (p<0.05 with 
Benjamini correction). D) The levels of four metabolites associated with peptidoglycan synthesis were 
significantly altered in ∆metB and ∆metNIQ∆metB mutants. UDP-MurNAc, UDP-N-acetyl-muraminate; 
UDP-MurNAc-L-Ala, UDP-N-acetyl-muramoyl-L-alanine; UDP-MurNAc-L-Ala-D-Glu, UDP-N-acetyl-
muramoyl-L-alanyl-D-glutamate; and UDP-MurNAc-L-Ala-γ-D-Glu-m-DAP, UDP-N-acetyl-muramoyl-
L-alanyl-D-glutamyl-meso-diaminopimelate. ∆metNIQ∆metB/pmetB-c’ denotes the complemented strain 
∆metNIQ∆metB pACYC184metB. Individual data points represent biological replicates, and the mean for 
each group is shown. One-way ANOVA with Bonferroni post-tests were used to compare the metabolite 
level in each mutant to wild-type, p-values <0.05 are shown: *, p<0.05; **, p<0.01; ***, p<0.001; and 
****, p<0.0001. 
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